{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-178993","form_type":"8-K/A","ticker":"HURA","cik":"0001498382","company_name":"TuHURA Biosciences, Inc./NV","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.129286+00:00","generated_at":"2026-05-17T14:29:11.721969+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kineta acquisition closed; Q1 2025 financials show $1.7M net loss and $13.2M deficit","bullets":["Cash $304K, total liabilities $14M, stockholders' deficit $13.2M as of March 31, 2025.","Net loss attributable to Kineta for Q1 2025 was $1.676M vs $10.238M in Q1 2024 on reduced R&D spend.","Accumulated deficit reached $184.6M; Kineta has going concern warning with insufficient cash for next 12 months.","Merger consideration includes up to $16.5M initial stock, $6.5M delayed stock, $12M cash (net of exclusivity credits and working capital adjustments)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-178993","json":"https://secwatch.observer/filing/0001193125-25-178993.json","markdown":"https://secwatch.observer/filing/0001193125-25-178993.md","text":"https://secwatch.observer/filing/0001193125-25-178993.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1498382/000119312525178993/0001193125-25-178993-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1498382/000119312525178993/d67982d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:29:11.721969+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}